 |
 |
|
|
RESÚMENES OCTUBRE 2007 |
Psychotic Disorders
& Antipsychotics
(Haga un click en la información del journal para acceder al resúmen)
5 –
doble-ciego o metanálisis; 4 – subanálisis
o simple ciego; 3 – revisión, abierto, básico; 2 – casos; 1 – opinión
5 - Cognition and Neurocognition: Effects of Risperidone,
Olanzapine, and Haloperidol
Mark J. Sergi,
Michael F. Green, Clifford Widmark, Christopher Reist, Stephen Erhart, David L. Braff, Kimmy S. Kee, Stephen R. Marder, and Jim Mintz
Am J Psychiatry 2007
164: 1585-1592
5 - The Cognitive and Negative
Symptoms in Schizophrenia Trial (CONSIST): The Efficacy of Glutamatergic
Agents for Negative Symptoms and Cognitive Impairments
Robert W. Buchanan, Daniel C. Javitt, Stephen R. Marder, Nina
R. Schooler, James M. Gold, Robert P. McMahon, Uriel Heresco-Levy, and William
T. Carpenter
Am J Psychiatry 2007
164: 1593-1602
3 - Insulin and Insulin-Like
Growth Factor-1 Abnormalities in Antipsychotic-Naive Schizophrenia
Ganesan Venkatasubramanian,
Seetharamaiah Chittiprol, Narendran Neelakantachar, Magadi N. Naveen, Jagadisha Thirthall, Bangalore N.
Gangadhar, and K. Taranath Shetty
Am J Psychiatry 2007
164: 1557-1560
3 - Lu
35-138 ((+)-(S)-3-{1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-3,6-dihydro-2H-pyridin-4-yl}-6-chloro-1H-indole),
a dopamine D4 receptor antagonist and serotonin reuptake inhibitor:
Characterisation of its in vitro profile and pre-clinical antipsychotic
potential
Peter Hertel, Michael Didriksen, Bruno Pouzet, Lise T.
Brennum, Karina K. Søby, Anna Kirstine Larsen, Claus T. Christoffersen, Teresa
Ramirez, Monica M. Marcus, Torgny H. Svensson, Vincenzo Di Matteo, Ennio
Esposito, Benny Bang-Andersen and Jørn Arnt
European Journal of Pharmacology. Volume 573, Issues 1-3, 14 November 2007, Pages
148-160
5 - Comparison of ziprasidone
and aripiprazole in acutely ill patients with
schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week
study
Zimbroff, Dan;
International
Clinical Psychopharmacology. 22(6):363-370, November 2007
4< - Risperidone alone versus
risperidone plus valproate
in the treatment of patients with schizophrenia and hostility
Citrome, Leslie; Shope,
Constance B; Nolan, Karen A; Czobor, Pal; Volavka, Jan
International Clinical Psychopharmacology.
22(6):356-362, November 2007
3 - Cognitive Improvement After Treatment With Second-Generation Antipsychotic
Medications in First-Episode Schizophrenia. Is It a Practice Effect?
Terry E. Goldberg, Robert S.
Goldman, Katherine E. Burdick, Anil K. Malhotra, Todd
Lencz, Raman C. Patel, Margaret G. Woerner, Nina R. Schooler, John
M. Kane, Delbert G. Robinson
Arch Gen Psychiatry. 2007;64:1115-1122
5 - A Systematic Review of
Mortality in Schizophrenia. Is the Differential Mortality Gap Worsening Over
Time?
Sukanta Saha,
David Chant, John McGrath
Arch Gen Psychiatry. 2007;64:1123-1131
3 -
Cholinergic hypothesis in psychosis following traumatic brain injury and
cholinergic hypothesis in schizophrenia: a link?
M. Bennouna,
V.B. Greene, L. Defranoux
L’ Encephale. Vol 33 - N° 4-C1 - Septembre 2007:616 - 620
3 -
Treatment of tobacco use in smokers with schizophrenia
A. Dervaux, X. Laqueille
L’Encephale. Vol 33 - N° 4-C1 - Septembre 2007 :629
- 632
3! -
Predictors of medication competence in schizophrenia patients
R. Walter Heinrichs, Joel O. Goldberg, Ashley A. Miles and Stephanie McDermid Vaz
Psychiatry
Research.
Article in Press, Oct 2007
3! -
Gender differences in response to antipsychotic treatment in outpatients with
schizophrenia
Judith Usall, David Suarez, Josep Maria Haro, and the SOHO Study Group
Psychiatry
Research.
Article in Press, Oct 2007
5! - Activation of mGlu2/3
receptors as a new approach to treat schizophrenia: a randomized Phase 2
clinical trial
Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V
Andreev, Alla S Avedisova,
Leonid M Bardenstein, Issak
Y Gurovich, Margarita A Morozova,
Sergey N Mosolov, Nikolai G Neznanov,
Alexander M Reznik, Anatoly B Smulevich,
Vladimir A Tochilov, Bryan G Johnson, James A Monn & Darryle D Schoepp
Nature Medicine 13, 1102 - 1107 (2007)
The CATIE
Schizophrenia Trial: Results, Impact, Controversy
Theo C. Manschreck;
Roger A. Boshes
Harvard Review of
Psychiatry, Volume 15, Issue 5 September 2007, pages 245 - 258
3 - Two weeks' quetiapine
treatment for schizophrenia, drug-induced psychosis and borderline personality
disorder: a naturalistic study with drug plasma levels
Massimo C Mauri
, Lucia S Volonteri, Alessio Fiorentini, Rodolfo Pirola & Silvio R Bareggi
Expert Opinion on Pharmacotherapy. October 2007, Vol. 8, No. 14, Pages 2207-2213
3 -
Paliperidone: a new extended-release oral atypical
antipsychotic
Heather Dlugosz & Henry A Nasrallah
Expert Opinion on Pharmacotherapy. October 2007, Vol. 8, No. 14, Pages 2307-2313
3 - Adverse Effects of Atypical Antipsychotics:
Differential Risk and Clinical Implications
Haddad, Peter M; Sharma, Sonu G
CNS Drugs. 21(11):911-936, 2007
3< -
Comparing Adherence to and Persistence with Antipsychotic Therapy Among Patients with Bipolar Disorder
Hassan M, Madhavan SS, Kalsekar ID, Makela EH, Rajagopalan K, Islam S, Kavookjian J,
Miller LA
Ann Pharmacother. 2007 Oct
9; [Epub ahead of print]
5 -
Efficacy and Tolerability of Asenapine in Acute
Schizophrenia: A Placebo- and Risperidone-Controlled
Trial
Steven G. Potkin,
Miriam Cohen, and John Panagides
J Clin Psychiatry 2007;68:1492-1500
3 -
Comparison of Metabolic Syndrome Incidence Among
Schizophrenia Patients Treated With Aripiprazole
Versus Olanzapine or Placebo
Gilbert J. L'Italien,
Daniel E. Casey, Hong J. Kan, William H. Carson, and Ronald N. Marcus
J Clin Psychiatry 2007;68:1510-1516
3! -
Early Prediction of Clinical Response in Schizophrenia Patients Receiving the
Atypical Antipsychotic Zotepine
Ching-Hua Lin, Li-Shiu
Chou, Chieh-Hsin Lin, Chih-Yao
Hsu, Yong-Shing Chen, and
J Clin Psychiatry 2007;68:1522-1527
3! -
Quetiapine and Drug Interactions: Evidence From a Routine Therapeutic Drug Monitoring Service
Ingrid Castberg, Eirik Skogvoll, and Olav Spigset
J Clin Psychiatry 2007;68:1540-1545
3< -
Comparing Adherence to and Persistence with Antipsychotic Therapy Among Patients with Bipolar Disorder
Mariam Hassan, S Suresh Madhavan, Iftekhar D Kalsekar, Eugene H Makela, Kitty Rajagopalan, Syed Islam, Jan Kavookjian, Lesley-Ann Miller
The Annals of
Pharmacotherapy: Vol. 41, No. 11, pp.
1812-1818
3! - Comparison of
the Effects of Thioridazine and Mesoridazine
on the QT Interval in Healthy Adults After Single Oral
Doses
I S M Salih, R H K Thanacoody, G
A McKay and S H L Thomas
Clinical Pharmacology & Therapeutics (2007) 82, 548–554
3 - Factors
Affecting Drug Concentrations and QT Interval During Thioridazine Therapy
R H K Thanacoody, A K Daly, J G Reilly, I
N Ferrier and S H L Thomas
Clinical Pharmacology & Therapeutics (2007) 82, 555–565
3 - Five-year
follow-up during antipsychotic treatment: efficacy, safety, functional and
social outcome
E. Lindström, J. Eberhard,
S. Levander
Acta Psychiatrica Scandinavica 2007; 116 (s435), 5–16
3 - Obstetric
complications and postpartum psychosis: a follow-up study of 1.1 million
first-time mothers between 1975 and 2003 in Sweden
A. Nager, K. Sundquist,
V. Ramírez-León, L. M. Johansson
Acta Psychiatrica Scandinavica (OnlineEarly
Articles) Nov 2007
Treatment
Guidelines for Non-Schizophrenic Psychotic Disorders?
Markus Jäger, Karel Frasch, Stefan Weinmann, Thomas
Becker
Psychiat Prax 2007; 34: 370-376
3 - Correlations
between fMRI activation and individual psychotic
symptoms in un-medicated subjects at high genetic risk of schizophrenia
Heather
C Whalley, Viktoria-Eleni Gountouna, Jeremy
Hall, Andrew McIntosh, Marie-Claire Whyte,
Enrico Simonotto, Dominic E Job, David GC Owens, Eve C Johnstone and Stephen M Lawrie
TEXTO GRATUITO
3! - A Review of the Effects of Modafinil on Cognition in Schizophrenia
Sharon Morein-Zamir, Danielle C. Turner and
Barbara J. Sahakian
Schizophrenia
Bulletin 2007 33(6):1298-1306
3! - Substance Use and Abuse in First-Episode
Psychosis: Prevalence Before and After Early Intervention
Suzanne Archie, Brian R. Rush, Noori Akhtar-Danesh, Ross Norman, Ashok Malla,
Paul Roy and Robert B. Zipursky
Schizophrenia
Bulletin 2007 33(6):1354-1363
3! - Socioeconomic Status at Birth Is
Associated With Risk of Schizophrenia: Population-Based Multilevel Study
Shirli Werner, Dolores Malaspina and Jonathan Rabinowitz
Schizophrenia
Bulletin 2007 33(6):1373-1378
3 - Treatment of Schizophrenia With Long-Acting Fluphenazine,
Haloperidol, or Risperidone
Mark Olfson, Steven C. Marcus and Haya Ascher-Svanum
Schizophrenia
Bulletin 2007 33(6):1379-1387
3! - Low baseline serotonin-2A
receptors predict clinical response to olanzapine in
first-episode schizophrenia patients
Belén Arranz, Pilar Rosel,
Luis San, Nicolás Ramírez,
Rosa María Dueñas, Josep Salavert, Meritxell Centeno and Enrique del
Moral
Psychiatry
Research.
Volume 153, Issue 2, 31 October 2007, Pages 103-109
3 - The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia
Edoardo Spina& Roberto Cavallaro
Expert Opinion on Drug Safety. November 2007, Vol. 6, No. 6, Pages 651-662
3! - MRI brain volume abnormalities
in young, nonpsychotic relatives of schizophrenia probands are associated with subsequent prodromal
symptoms
Beng-Choon Ho
Schizophrenia
Research.
Volume 96, Issues 1-3, November 2007, Pages 1-13
3< - Medium term follow-up of a
randomized controlled trial of interventions for young people at ultra high
risk of psychosis
Lisa J. Phillips,
Patrick D. McGorry, Hok Pan
Yuen, Janine Ward, Kerri Donovan, Daniel Kelly, Shona
M. Francey and Alison R. Yung
Schizophrenia
Research.
Volume 96, Issues 1-3, November 2007, Pages 25-33
4 - Cognition, functioning and
quality of life in schizophrenia treatment: Results of a one-year randomized
controlled trial of olanzapine and quetiapine
L.P. Voruganti, A.G. Awad, G. Parker,
C. Forrest, Y. Usmani, M.L.D. Fernando and S. Senthilal
Schizophrenia
Research.
Volume 96, Issues 1-3, November 2007, Pages 146-155
3 - The neuropsychological
correlates of cannabis use in schizophrenia: Lifetime abuse/dependence,
frequency of use, and recency of use
Carissa M. Coulston, Michael Perdices and
Christopher C. Tennant
Schizophrenia
Research.
Volume 96, Issues 1-3, November 2007, Pages 169-184
3 - Planning for the optimal design
of studies to personalize antipsychotic prescriptions in the post-CATIE era:
The clinical and pharmacoepidemiological data suggest
that pursuing the pharmacogenetics of metabolic
syndrome complications (hypertension, diabetes mellitus and hyperlipidemia)
may be a reasonable strategy
Jose de Leon and
Francisco J. Diaz
Schizophrenia
Research.
Volume 96, Issues 1-3, November 2007, Pages 185-197
3 - Stress Sensitization in Schizophrenia
KUNIO
YUII, MICHIO SUZUKI AND MASAYOSHI KURACHI
Ann. N.Y. Acad. Sci. 1113: 276–290 (2007)
3 - Cannabis use and psychosis: the
origins and implications of an association
John Macleod
Advances in Psychiatric Treatment (2007) 13:
400-411
3< - Gender differences in response
to antipsychotic treatment in outpatients with schizophrenia
Judith Usall, David Suarez, Josep Maria Haro and the SOHO Study Group
Psychiatry
Research.
Volume 153, Issue 3, 3 December 2007, Pages 225-231
3 - Complementary Therapies for
Schizophrenia: Expanding the Clinician's Toolbox
Psych Times. septiembre
09, 2007
Psychopharmacology Bulletin.
2007;40(2):6-18
Psychopharmacology
Bulletin. 2007;40(2):82-100
3 - Simple Options for Improving Signal Detection in
Antidepressant Clinical Trials
Craig H.
Mallinckrodt, Adam L. Meyers, Apurva Prakash, Douglas E. Faries, and
Michael J. Detke